REDWOOD CITY - Rezolute, Inc. (Nasdaq: RZLT) ('Rezolute' or the 'Company'), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled 'An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study' will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be held May 2-5, 2024 at the Sheraton Grand Chicago Riverwalk.

Paul Thorton, M.D., of Cook Children's Medical Center in Fort Worth, Texas, will present the poster, which details findings from the Company's Phase 2 RIZE study evaluating the treatment of congenital hyperinsulinism (HI) with RZ358 in pediatric patients. While primary and key secondary glycemic endpoints (weekly events and daily percent time) from the RZ358-606 (RIZE) study have been previously reported, the current sub-analyses highlight the benefits of RZ358 during the vulnerable overnight fasting period, utilizing continuous glucose monitor (CGM) to evaluate average time in hypoglycemia (

(C) 2024 Electronic News Publishing, source ENP Newswire